Protection against lethal HAdV-4 challenge in STAT1 mice by novel human monoclonal antibodies
Overall, mAb 2CF4 represents a promising candidate for safe and effective prophylactic and therapeutic strategies against HAdV-4 infection.
Authors
- Wei Chen (ORCID: https://orcid.org/0000-0001-5805-2469)
- Guanying Zhang (ORCID: https://orcid.org/0000-0003-3372-3355)
- Xiangyang Chi (ORCID: https://orcid.org/0000-0002-0580-5997)
- You Yang (ORCID: https://orcid.org/0000-0003-4438-2162)
- Busen Wang (ORCID: https://orcid.org/0000-0001-9041-1919)
- Chao Cheng (ORCID: https://orcid.org/0000-0003-4330-9342)
- Jianmin Li (ORCID: https://orcid.org/0000-0002-2827-2185)
- Xinyi Zhang (ORCID: https://orcid.org/0000-0003-2955-0658)
- Zhu Zhang (ORCID: https://orcid.org/0000-0001-5009-4680)
- Peng Zhai (ORCID: https://orcid.org/0000-0001-6196-2658)
- Ting Fang (ORCID: https://orcid.org/0000-0002-8963-7176)
- Peng Lv (ORCID: https://orcid.org/0000-0003-4962-3463)
- Yunzhu Dong (ORCID: https://orcid.org/0000-0003-4266-7295)
Institutions
- Nanjing University of Chinese Medicine (CN)
- Beijing VDJBio (China) (CN)
- Czech Academy of Sciences, Institute of Biotechnology (CZ)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-19
- DOI
- https://doi.org/10.3389/fimmu.2025.1613945
- Citations
- 1
- Primary Topic
- Immunodeficiency and Autoimmune Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.80